Filterlex Medical

Company Overview

Snapshot

Founded in June 2015 by Giora Weisz, Ron Davidson, Sigal Eli, and Eyal Teichman, Filterlex Medical operates with 1–10 employees. The company has raised a total of $19.49M across 9 funding rounds from 4 investors. In July 2024, Filterlex Medical secured a funding round led by.

Business overview

Filterlex Medical is a medical device startup specializing in embolic protection. The company develops the Captis, a full-body embolic protection device designed for easy deployment and retrieval. Positioned in the aorta, the Captis protects the aortic surface and facilitates seamless Transcatheter Aortic Valve Implantation (TAVI) procedures. Its triple-action design works by deflecting, capturing, and removing embolic particles, requiring no additional access and integrating smoothly into existing workflow. Filterlex Medical operates within the Health Tech & Life Sciences sector, specifically in Medical Devices and Medical Treatment & Therapeutics, serving healthcare providers in cardiovascular medicine.

Strategic signal

In May 2022, Filterlex Medical announced positive results from a first-in-human study for its Captis full-body embolic protection device. This milestone is a significant validation of the device's safety and efficacy, indicating strong progress in its clinical development and de-risking the technology for future regulatory approvals and market entry. For investors, this signals a critical step towards commercialization and potential for addressing unmet needs in cardiovascular procedures.

Company Intelligence Q&A

What is Filterlex Medical's primary product?

Filterlex Medical's primary product is the Captis, a full-body embolic protection device designed to prevent embolic particles from reaching the brain and other organs during cardiovascular procedures like TAVI.

When did Filterlex Medical last raise funding?

Filterlex Medical secured a funding round in July 2024, led by Katao Venture Partners.

What was a key development for the Captis device in 2022?

In May 2022, Filterlex Medical announced positive results from a first-in-human study for the Captis full-body embolic protection device, demonstrating its potential in clinical settings.

Which organization backed Filterlex Medical's embolic protection device in 2019?

In September 2019, the European Commission Horizon 2020 Program backed Filterlex Medical's embolic protection device, Captis.

What was a significant funding event for Filterlex Medical in November 2021?

In November 2021, Filterlex Medical closed a Series A1 investment to accelerate the Captis cardiovascular clinical program.